A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Sponsor: Eli Lilly and Company
Listed as NCT07226843, this observational or N/A phase trial focuses on Follicular Lymphoma and Lymphoma, Diffuse Large B-Cell and remains actively recruiting participants. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Apr 18, 2026 — Present [daily]
Not Yet Recruiting
Phase: PHASE1 → None
-
Mar 2026 — Apr 2026 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States , Barcelona, Spain , Berlin, Germany , Bologna, Italy , Boston, United States , Boston, United States , Chiba, Japan , Cologne, Germany , Columbus, United States , Dallas, United States and 35 more locations